Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA updates LDL-C lowering indication for Nexletol (bempedoic acid) tablet and Nexlizet (bempedoic acid and ezetimibe) tablet – Esperion

Written by | 2 Jan 2024

Esperion announced that the FDA has approved an updated LDL-cholesterol lowering indication for Nexletol and Nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.